Cosmo is a speciality pharmaceutical company that aims to become a global leader in the market of optimised therapies for selected gastro-intestinal diseases.
Find out more about us
Cosmo’s product portfolio strategy is focused on the treatment of diseases of the colon, primarily on Inflammatory Bowel Diseases (IBD).
The experience gained by years of manufacturing was the basis for the establishment of the MMX® technology. It allows the delivery of active pharmaceutical ingredients into the lumen of the colon through tablets in a delayed and controlled extent with the effect that the pharmaceutical products can be applied to the full length of the colon.
The blend of our knowledge of the colon and the unique characteristics of the MMX® technology gives us a strong competitive edge in developing new applications for the colon without having to resort to the expensive and risky pure research process for new chemical entities.
(Delayed by 15 minutes)
-0.80 (-0.54%) 10:27 26 Nov 2014
Detailed share price
24 Nov 2014
Cosmo to seek shareholders approval for the cancellation of up to 576’760 treasury shares at Extraordinary Shareholders Meeting which is to take place on December 22, 2014
24-26 Nov 2014
German Equity Forum in Frankfurt
View desktop site